Effects of vitellizumab on the immune microenvironment of patients with ulcerative colitis of different severities
Objective To analyze the effect of vitellizumab on immune microenvironment in patients with ulcerative colitis of different severity.Methods A total of 103 patients with ulcerative colitis admitted to the First People's Hospital of Xiaoshan District,Hangzhou City,from December 2021 to December 2023,were selected as the study subjects.The propensity score was matched to adjust the balance of patients data.After successful matching,46 patients were obtained in each group.The control group was treated with mesalazine,while the ob-servation group was treated with vitalizole on the basis of the control group.The immune microenvironment of the two groups were compared before and after treatment.The dynamic changes of immune microenvironment in the two groups were analyzed by repeated measurement ANOVA.The clinical efficacy of the two groups was com-pared.A generalized estimating equation model was established to compare the differences in clinical efficacy a-mong different time points,groups,and disease severities.Results There was no significant difference in baseline data between the observation group and the control group after matching(P＞0.05).After treatment,IL-6,IL-10,CD8+,Th17 and Th17/Treg were all decreased in both groups(P＜0.05),and the observation group was lower than the control group(P＜0.05);TNF-α,CD4+,Treg and CD4+/CD8+were all increased in both group(P＜0.05),and the observation group was higher than the control group(P＜0.05).The results of repeated measures analysis of vari-an-ce showed that the time effect,group effect and interaction effect of dynamic changes in immune microenvironment indicators between the two groups were statistically significant(P＜0.05).The total effective rate of treatment in the observation group(84.8％)was higher than that of the control group(63.0％)(P＜0.05).There was no significant difference in clinical efficacy between the two groups for patients with mild ulcerative colitis(P＞0.05).For patients with moderate and severe ulcerative colitis,the effect of the observation group at different times was better than that of the control group(P＜0.05).Conclusions Vitellizumab has a certain influence on the immune microenvi-ronment of patients with different severities of ulcerative colitis,and has certain advantages in the treatment of patients with moderate and severe ulcerative colitis.
万方数据
维普
